Aptose Biosciences Inc
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in mye… Read more
Aptose Biosciences Inc (APTO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: 1.774x
Based on the latest financial reports, Aptose Biosciences Inc (APTO) has a cash flow conversion efficiency ratio of 1.774x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.06 Million) by net assets ($-4.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aptose Biosciences Inc - Cash Flow Conversion Efficiency Trend (1996–2024)
This chart illustrates how Aptose Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Aptose Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aptose Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Afluente Transmissão de Energia Elétrica S.A
SA:AFLT3
|
0.067x |
|
Charles & Colvard Ltd
NASDAQ:CTHR
|
-0.051x |
|
Smart Logistics Global Limited Ordinary Shares
NASDAQ:SLGB
|
-0.051x |
|
LSE GROUP - Dusseldorf Stock Exchang
DU:LS4C
|
N/A |
|
BILFINGER (GBF.SG)
STU:GBF
|
0.030x |
|
Group One Capital Limited
AU:G1C
|
0.083x |
|
Pacific Smiles Group Ltd
AU:PSQ
|
0.382x |
|
Ortin Global Limited
NSE:ORTINGLOBE
|
-0.597x |
Annual Cash Flow Conversion Efficiency for Aptose Biosciences Inc (1996–2024)
The table below shows the annual cash flow conversion efficiency of Aptose Biosciences Inc from 1996 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-4.54 Million | $-35.98 Million | 7.919x | -48.48% |
| 2023-12-31 | $-2.90 Million | $-44.59 Million | 15.371x | +1894.75% |
| 2022-12-31 | $37.74 Million | $-32.32 Million | -0.856x | -46.82% |
| 2021-12-31 | $74.24 Million | $-43.30 Million | -0.583x | -104.68% |
| 2020-12-31 | $118.92 Million | $-33.89 Million | -0.285x | -24.17% |
| 2019-12-31 | $93.93 Million | $-21.56 Million | -0.230x | +86.07% |
| 2018-12-31 | $14.08 Million | $-23.21 Million | -1.648x | -64.47% |
| 2017-12-31 | $10.20 Million | $-10.22 Million | -1.002x | +39.69% |
| 2016-12-31 | $7.33 Million | $-12.17 Million | -1.661x | -129.30% |
| 2015-12-31 | $13.65 Million | $-9.89 Million | -0.725x | -84.19% |
| 2014-12-31 | $25.28 Million | $-9.94 Million | -0.393x | -106.04% |
| 2013-12-31 | $-757.75K | $-4.94 Million | 6.516x | +296.38% |
| 2012-12-31 | $-1.95 Million | $-3.21 Million | 1.644x | +106.67% |
| 2011-12-31 | $244.66K | $-6.03 Million | -24.661x | -459.21% |
| 2010-12-31 | $-513.68K | $-3.53 Million | 6.865x | +694.85% |
| 2009-12-31 | $-7.66 Million | $-6.62 Million | 0.864x | -67.36% |
| 2008-12-31 | $-3.87 Million | $-10.25 Million | 2.646x | +131.98% |
| 2007-12-31 | $711.16K | $-5.88 Million | -8.274x | -261.85% |
| 2006-12-31 | $-2.32 Million | $-11.87 Million | 5.112x | +462.25% |
| 2005-12-31 | $10.57 Million | $-14.92 Million | -1.411x | 0.00% |
| 2004-12-31 | $10.57 Million | $-14.92 Million | -1.411x | -43.83% |
| 2003-12-31 | $20.99 Million | $-20.60 Million | -0.981x | -263.72% |
| 2002-12-31 | $28.89 Million | $-7.79 Million | -0.270x | 0.00% |
| 2001-12-31 | $28.89 Million | $-7.79 Million | -0.270x | -56.21% |
| 2000-12-31 | $36.38 Million | $-6.28 Million | -0.173x | -121.46% |
| 1999-12-31 | $45.89 Million | $-3.58 Million | -0.078x | +95.88% |
| 1998-12-31 | $1.29 Million | $-2.44 Million | -1.895x | -106.70% |
| 1997-12-31 | $3.30 Million | $-3.02 Million | -0.917x | -141.90% |
| 1996-12-31 | $6.89 Million | $-2.61 Million | -0.379x | -- |